Buserelin record · updated 16h ago
Buserelin is a synthetic analogue of gonadorelin, a naturally occurring gonadotropin-releasing hormone (GnRH). It acts primarily on the anterior pituitary gland to stimulate the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which are critical for regulating reproductive processes in both males and females. The mechanism of action involves binding to GnRH receptors, leading to a cascade of hormonal releases that promote gonadal function.
How it works: GnRH receptor agonist
Development stage
where Buserelin sits between preclinical work and regulatory approval- 1CurrentPreclinicalAnimal / in-vitro work
- 2Not reachedPhase 1Safety in humans
- 3Not reachedPhase 2Efficacy signal
- 4Not reachedPhase 3Confirmatory trials
- 5Not reachedApprovedCleared by a regulator
Stage is inferred from the highest trial phase in the indexed corpus and 53 registered trials. It describes the research record, not a recommendation.
Mass and formula from PubChem CID 50225. No verified residue count for this compound.
What people are saying
anecdotal · not evidenceUnverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Buserelin will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.